Novartis (NVS) Reports Positive Long-Term Data on CSU Drug
Novartis (NVS) reports phase III data that confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria.
Novartis leukemia drug more effective than older treatments in trial
Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care drugs in a late-stage study with details presented on Friday.
Novartis (NVS) Presents Positive Data on Renal Drugs at ERA
Novartis (NVS) presents data on Fabhalta in adult patients with C3 glomerulopathy and atrasentan in those with IgA nephropathy (IgAN) at the ERA.
Novartis: Buy This Blue-Chip Dividend Stock On Sale Now
Novartis is a business that has shown tremendous resiliency, operating for hundreds of years. The multinational Swiss pharmaceutical topped the analyst consensus for revenue and core EPS in Q1. Novartis' net debt load is minimal, which justifies its prime credit rating from S&P.
